Clinical and molecular phenotype of Aicardi-Goutieres syndrome.

5' exonuclease TREX1 and the three subunits of the RNASEH2 endonuclease complex. To define the molecular spectrum of AGS, we performed mutation screening in patients, from 127 pedigrees, with a clinical diagnosis of the disease. Biallelic mutations in TREX1, RNASEH2A, RNASEH2B, and RNASEH2C were observed in 31, 3, 47, and 18 families, respectively. In five families, we identified an RNASEH2A or RNASEH2B mutation on one allele only. In one child, the disease occurred because of a de novo heterozygous TREX1 mutation. In 22 families, no mutations were found. Null mutations were common in TREX1, although a specific missense mutation was observed frequently in patients from northern Europe. Almost all mutations in RNASEH2A, RNASEH2B, and RNASEH2C were missense. We identified an RNASEH2C founder mutation in 13 Pakistani families. We also collected clinical data from 123 mutation-positive patients. Two clinical presentations could be delineated: an early-onset neonatal form, highly reminiscent of congenital infection seen particularly with TREX1 mutations, and a later-onset presentation, sometimes occurring after several months of normal development and occasionally associated with remarkably preserved neurological function, most frequently due to RNASEH2B mutations. Mortality was correlated with genotype; 34.3% of patients with TREX1, RNASEH2A, and RNASEH2C mutations versus 8.0% RNASEH2B mutation-positive patients were known to have died (P=.001). Our analysis defines the phenotypic spectrum of AGS and suggests a coherent mutation-screening strategy in this heterogeneous disorder. Additionally, our data indicate that at least one further AGS-causing gene remains to be identified. -->
References: Am J Hum Genet. 2007 Apr;80(4):811-5. (PMID: 17357087)
Immunity. 2006 Sep;25(3):383-92. (PMID: 16979570)
Nat Genet. 2000 Jun;25(2):135-6. (PMID: 10835621)
Am J Hum Genet. 2000 Jul;67(1):213-21. (PMID: 10827106)
Neuropediatrics. 2000 Jun;31(3):113. (PMID: 10963096)
Neuropediatrics. 2000 Jun;31(3):155-8. (PMID: 10963105)
Eur J Paediatr Neurol. 2002;6 Suppl A:A47-53; discussion A55-8, A77-86. (PMID: 12365361)
J Med Genet. 2003 Mar;40(3):183-7. (PMID: 12624136)
Am J Med Genet A. 2003 Jul 15;120A(2):261-5. (PMID: 12833411)
N Engl J Med. 2003 Aug 14;349(7):691-700. (PMID: 12917307)
Neurology. 2003 Sep 9;61(5):642-7. (PMID: 12963755)
Acta Paediatr Scand. 1970 Mar;59(2):185-91. (PMID: 5442429)
Ann Neurol. 1984 Jan;15(1):49-54. (PMID: 6712192)
Clin Genet. 1986 Aug;30(2):112-6. (PMID: 3757300)
J Neurol Sci. 1988 Apr;84(2-3):201-8. (PMID: 2837539)
Am J Med Genet. 1994 Aug 1;52(1):58-65. (PMID: 7977464)
J Med Genet. 1995 Nov;32(11):881-4. (PMID: 8592332)
Neuropediatrics. 1998 Jun;29(3):163-7. (PMID: 9706629)
Ann Neurol. 1998 Dec;44(6):900-7. (PMID: 9851434)
Neuropediatrics. 2005 Feb;36(1):40-4. (PMID: 15776321)
J Pediatr. 2005 May;146(5):701-5. (PMID: 15870678)
Neurology. 2005 May 10;64(9):1621-4. (PMID: 15883328)
Prenat Diagn. 2005 May;25(5):362-4. (PMID: 15906425)
Nat Rev Mol Cell Biol. 2005 Sep;6(9):677-88. (PMID: 16103871)
Fetal Diagn Ther. 2006;21(1):153-5. (PMID: 16354995)
Neuropediatrics. 2005 Dec;36(6):399-402. (PMID: 16429382)
J Med Genet. 2006 May;43(5):444-50. (PMID: 15908569)
Nat Genet. 2006 Aug;38(8):917-20. (PMID: 16845398)
Nat Genet. 2006 Aug;38(8):910-6. (PMID: 16845400)
Immunity. 2006 Sep;25(3):373-81. (PMID: 16979569)
J Biol Chem. 2007 Apr 6;282(14):10537-43. (PMID: 17293595)
Grant Information: K08 NS060695 United States NS NINDS NIH HHS; MC_U127580972 United Kingdom MRC_ Medical Research Council
Molecular Sequence: GENBANK AAK07616
RefSeq NM_033627
Substance Nomenclature: 0 (Phosphoproteins)
EC 3.1.- (Exodeoxyribonucleases)
EC 3.1.16.- (three prime repair exonuclease 1)
EC 3.1.26.- (ribonuclease HII)
EC 3.1.26.4 (Ribonuclease H)
Entry Date(s): Date Created: 20070912 Date Completed: 20071030 Latest Revision: 20220129
Update Code: 20240829
PubMed Central ID: PMC2227922
DOI: 10.1086/521373
PMID: 17846997
Autor: Rice G; Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, LS9 7TF, UK., Patrick T, Parmar R, Taylor CF, Aeby A, Aicardi J, Artuch R, Montalto SA, Bacino CA, Barroso B, Baxter P, Benko WS, Bergmann C, Bertini E, Biancheri R, Blair EM, Blau N, Bonthron DT, Briggs T, Brueton LA, Brunner HG, Burke CJ, Carr IM, Carvalho DR, Chandler KE, Christen HJ, Corry PC, Cowan FM, Cox H, D'Arrigo S, Dean J, De Laet C, De Praeter C, Dery C, Ferrie CD, Flintoff K, Frints SG, Garcia-Cazorla A, Gener B, Goizet C, Goutieres F, Green AJ, Guet A, Hamel BC, Hayward BE, Heiberg A, Hennekam RC, Husson M, Jackson AP, Jayatunga R, Jiang YH, Kant SG, Kao A, King MD, Kingston HM, Klepper J, van der Knaap MS, Kornberg AJ, Kotzot D, Kratzer W, Lacombe D, Lagae L, Landrieu PG, Lanzi G, Leitch A, Lim MJ, Livingston JH, Lourenco CM, Lyall EG, Lynch SA, Lyons MJ, Marom D, McClure JP, McWilliam R, Melancon SB, Mewasingh LD, Moutard ML, Nischal KK, Ostergaard JR, Prendiville J, Rasmussen M, Rogers RC, Roland D, Rosser EM, Rostasy K, Roubertie A, Sanchis A, Schiffmann R, Scholl-Burgi S, Seal S, Shalev SA, Corcoles CS, Sinha GP, Soler D, Spiegel R, Stephenson JB, Tacke U, Tan TY, Till M, Tolmie JL, Tomlin P, Vagnarelli F, Valente EM, Van Coster RN, Van der Aa N, Vanderver A, Vles JS, Voit T, Wassmer E, Weschke B, Whiteford ML, Willemsen MA, Zankl A, Zuberi SM, Orcesi S, Fazzi E, Lebon P, Crow YJ
Jazyk: angličtina
Zdroj: American journal of human genetics [Am J Hum Genet] 2007 Oct; Vol. 81 (4), pp. 713-25. Date of Electronic Publication: 2007 Sep 04.
DOI: 10.1086/521373
Abstrakt: Aicardi-Goutieres syndrome (AGS) is a genetic encephalopathy whose clinical features mimic those of acquired in utero viral infection. AGS exhibits locus heterogeneity, with mutations identified in genes encoding the 3'-->5' exonuclease TREX1 and the three subunits of the RNASEH2 endonuclease complex. To define the molecular spectrum of AGS, we performed mutation screening in patients, from 127 pedigrees, with a clinical diagnosis of the disease. Biallelic mutations in TREX1, RNASEH2A, RNASEH2B, and RNASEH2C were observed in 31, 3, 47, and 18 families, respectively. In five families, we identified an RNASEH2A or RNASEH2B mutation on one allele only. In one child, the disease occurred because of a de novo heterozygous TREX1 mutation. In 22 families, no mutations were found. Null mutations were common in TREX1, although a specific missense mutation was observed frequently in patients from northern Europe. Almost all mutations in RNASEH2A, RNASEH2B, and RNASEH2C were missense. We identified an RNASEH2C founder mutation in 13 Pakistani families. We also collected clinical data from 123 mutation-positive patients. Two clinical presentations could be delineated: an early-onset neonatal form, highly reminiscent of congenital infection seen particularly with TREX1 mutations, and a later-onset presentation, sometimes occurring after several months of normal development and occasionally associated with remarkably preserved neurological function, most frequently due to RNASEH2B mutations. Mortality was correlated with genotype; 34.3% of patients with TREX1, RNASEH2A, and RNASEH2C mutations versus 8.0% RNASEH2B mutation-positive patients were known to have died (P=.001). Our analysis defines the phenotypic spectrum of AGS and suggests a coherent mutation-screening strategy in this heterogeneous disorder. Additionally, our data indicate that at least one further AGS-causing gene remains to be identified.
Databáze: MEDLINE
Externí odkaz: